Insulet Stock Price, News & Analysis (NASDAQ:PODD)

$75.18 2.29 (3.14 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$75.18
Today's Range$72.81 - $75.44
52-Week Range$38.43 - $78.65
Volume662,461 shs
Average Volume471,172 shs
Market Capitalization$4.37 billion
P/E Ratio-150.36
Dividend YieldN/A
Beta1.58

About Insulet (NASDAQ:PODD)

Insulet logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Prosthetics
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Debt-to-Equity Ratio4.65%
Current Ratio4.88%
Quick Ratio4.42%

Price-To-Earnings

Trailing P/E Ratio-150.36
Forward P/E Ratio-174.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$366.99 million
Price / Sales11.92
Cash FlowN/A
Price / CashN/A
Book Value$1.10 per share
Price / Book68.35

Profitability

Trailing EPS($0.50)
Net Income$-28,870,000.00
Net Margins-6.66%
Return on Equity-43.85%
Return on Assets-6.26%

Miscellaneous

Employees640
Outstanding Shares58,190,000

Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its earnings results on Thursday, November, 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.06. The medical instruments supplier had revenue of $121.80 million for the quarter, compared to analyst estimates of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The company's quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) earnings per share. View Insulet's Earnings History.

When will Insulet make its next earnings announcement?

Insulet is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Insulet.

Where is Insulet's stock going? Where will Insulet's stock price be in 2018?

16 analysts have issued 1 year price objectives for Insulet's shares. Their forecasts range from $44.00 to $80.00. On average, they expect Insulet's stock price to reach $62.14 in the next year. View Analyst Ratings for Insulet.

What are Wall Street analysts saying about Insulet stock?

Here are some recent quotes from research analysts about Insulet stock:

  • 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (1/9/2018)
  • 2. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
  • 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
  • 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)

Who are some of Insulet's key competitors?

Who are Insulet's key executives?

Insulet's management team includes the folowing people:

  • Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer (Age 65)
  • Shacey Petrovic, President, Chief Operating Officer (Age 43)
  • Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer (Age 43)
  • Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development (Age 59)
  • David Colleran J.D., Senior Vice President, General Counsel, Secretary (Age 45)
  • Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering (Age 58)
  • Charles Alpuche, Senior Vice President - Global Manufacturing and Operations (Age 57)
  • Michael Spears, Senior Vice President - Quality and Regulatory Affairs (Age 52)
  • Bret Christensen, Chief Commercial Officer
  • Jessica Hopfield Ph.D., Lead Independent Director (Age 52)

Who owns Insulet stock?

Insulet's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (3.60%), Schwab Charles Investment Management Inc. (0.48%), KAMES CAPITAL plc (0.41%) and Diversified Trust Co (0.01%). Company insiders that own Insulet stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, James C Mullen, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet.

Who bought Insulet stock? Who is buying Insulet stock?

Insulet's stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, KAMES CAPITAL plc, Schwab Charles Investment Management Inc. and Diversified Trust Co. Company insiders that have bought Insulet stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet.

How do I buy Insulet stock?

Shares of Insulet can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of Insulet stock can currently be purchased for approximately $75.18.

How big of a company is Insulet?

Insulet has a market capitalization of $4.37 billion and generates $366.99 million in revenue each year. The medical instruments supplier earns $-28,870,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Insulet employs 640 workers across the globe.

How can I contact Insulet?

Insulet's mailing address is 600 TECHNOLOGY PARK SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  410 (Vote Outperform)
Underperform Votes:  361 (Vote Underperform)
Total Votes:  771
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insulet (NASDAQ:PODD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.672.602.57
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $62.14$60.77$55.46$47.42
Price Target Upside: 9.62% downside13.31% downside8.97% downside7.80% downside

Insulet (NASDAQ:PODD) Consensus Price Target History

Price Target History for Insulet (NASDAQ:PODD)

Insulet (NASDAQ:PODD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018Raymond James FinancialUpgradeMarket Perform -> Outperform$80.00HighView Rating Details
12/13/2017BarclaysReiterated RatingBuy$78.00LowView Rating Details
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$55.00 -> $63.00N/AView Rating Details
11/3/2017Jefferies GroupBoost Price TargetBuy$58.00 -> $67.00N/AView Rating Details
11/3/2017Robert W. BairdBoost Price TargetOutperform$65.00 -> $72.00N/AView Rating Details
11/1/2017Canaccord GenuityUpgradeHold -> Buy$50.00 -> $65.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$65.00 -> $74.00N/AView Rating Details
10/10/2017WedbushReiterated RatingBuy$60.00 -> $65.00N/AView Rating Details
8/4/2017OppenheimerSet Price TargetHold$55.00LowView Rating Details
8/4/2017Northland SecuritiesReiterated RatingBuyLowView Rating Details
8/4/2017CowenReiterated RatingOutperform$52.00 -> $63.00HighView Rating Details
7/17/2017BTIG ResearchDowngradeBuy -> NeutralMediumView Rating Details
5/25/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$47.00LowView Rating Details
5/14/2017B. RileyReiterated RatingNeutral$44.00LowView Rating Details
2/27/2017Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
11/17/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
2/26/2016BenchmarkUpgradeHold -> Buy$30.00 -> $40.00N/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Insulet (NASDAQ:PODD) Earnings History and Estimates Chart

Earnings by Quarter for Insulet (NASDAQ:PODD)

Insulet (NASDAQ PODD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.08)N/AView Earnings Details
11/2/2017Q3 2017($0.10)($0.04)$114.02 million$121.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.13)$106.23 million$110.00 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.16)($0.17)$97.73 million$101.70 millionViewListenView Earnings Details
2/27/2017Q416($0.05)($0.16)$100.61 million$103.58 millionViewListenView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.30)($0.30)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.35)($0.36)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.38)($0.37)ViewN/AView Earnings Details
2/9/2010Q4 2009($0.50)($0.43)ViewN/AView Earnings Details
10/26/2009Q3 2009($0.70)($0.88)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.67)($0.73)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.65)($0.71)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.63)($0.72)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.74)($0.75)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.71)($0.87)ViewN/AView Earnings Details
5/13/2008Q1 2008($0.52)($0.73)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.50)($0.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Insulet (NASDAQ:PODD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($0.11)$0.02($0.06)
Q2 20185($0.11)$0.05($0.02)
Q3 20184($0.10)$0.14$0.02
Q4 20184($0.09)$0.06($0.01)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Insulet (NASDAQ:PODD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insulet (NASDAQ PODD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.90%
Insider Trades by Quarter for Insulet (NASDAQ:PODD)
Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Insulet (NASDAQ PODD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017James C. MullenDirectorBuy2,500$67.45$168,625.00View SEC Filing  
9/6/2017Charles AlpucheEVPBuy2,500$58.08$145,200.00View SEC Filing  
5/16/2017Michael P. SpearsSVPBuy2,500$40.59$101,475.00View SEC Filing  
5/11/2017Bradley A. ThomasEVPBuy3,000$38.69$116,070.00View SEC Filing  
5/11/2017Jessica HopfieldDirectorBuy2,580$38.68$99,794.40View SEC Filing  
5/1/2017David A. LemoineDirectorSell1,524$43.40$66,141.60View SEC Filing  
3/13/2017Regina O. SommerDirectorSell40,000$45.00$1,800,000.00View SEC Filing  
3/6/2017David A. LemoineDirectorSell1,282$45.15$57,882.30View SEC Filing  
3/2/2017Joseph S. ZakrzewskiDirectorSell40,000$46.86$1,874,400.00View SEC Filing  
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.9820,330View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00202,795View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.2551,315View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.2848,340View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.1125,358View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.459,813View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.308,838View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.0079,668View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.3953,246View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.2458,246View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.7524,000View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.4177,316View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00184,293View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.0063,081View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.0077,316View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00184,293View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08118,194View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00118,194View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00182,433View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.007,000View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.0016,500View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insulet (NASDAQ PODD) News Headlines

Source:
DateHeadline
Insulet Co. (PODD) Given Average Rating of "Buy" by BrokeragesInsulet Co. (PODD) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 20 at 12:02 AM
Does Insulet Corporation’s (NASDAQ:PODD) Past Performance Indicate A Stronger Future?Does Insulet Corporation’s (NASDAQ:PODD) Past Performance Indicate A Stronger Future?
finance.yahoo.com - January 15 at 10:04 AM
$125.25 Million in Sales Expected for Insulet Co. (PODD) This Quarter$125.25 Million in Sales Expected for Insulet Co. (PODD) This Quarter
www.americanbankingnews.com - January 11 at 12:40 PM
Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by ...Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by ...
www.prnewswire.com - January 10 at 4:41 PM
Insulet (PODD) Cut to "Sell" at Zacks Investment ResearchInsulet (PODD) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 9 at 10:36 AM
Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by Signing Commercial AgreementAscensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by Signing Commercial Agreement
www.prnewswire.com - January 9 at 10:08 AM
-$0.08 EPS Expected for Insulet Co. (PODD) This Quarter-$0.08 EPS Expected for Insulet Co. (PODD) This Quarter
www.americanbankingnews.com - January 9 at 7:32 AM
4 Tailwinds Driving Raymond James Insulet Bull Case4 Tailwinds Driving Raymond James' Insulet Bull Case
finance.yahoo.com - January 8 at 4:48 PM
Insulet (PODD) Indicated Higher as Medicare Part D May Now Cover OmnipodInsulet (PODD) Indicated Higher as Medicare Part D May Now Cover Omnipod
www.streetinsider.com - January 8 at 4:48 PM
Insulet (PODD) Upgraded at Raymond James FinancialInsulet (PODD) Upgraded at Raymond James Financial
www.americanbankingnews.com - January 8 at 8:48 AM
Insulet (PODD) Upgraded to Outperform by UBS GroupInsulet (PODD) Upgraded to Outperform by UBS Group
www.americanbankingnews.com - January 8 at 8:02 AM
Insulet Co. (PODD) Receives Average Rating of "Buy" from BrokeragesInsulet Co. (PODD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 26 at 12:06 AM
 Brokerages Anticipate Insulet Co. (PODD) Will Post Quarterly Sales of $125.25 Million Brokerages Anticipate Insulet Co. (PODD) Will Post Quarterly Sales of $125.25 Million
www.americanbankingnews.com - December 25 at 6:38 AM
ETFs with exposure to Insulet Corp. : December 19, 2017ETFs with exposure to Insulet Corp. : December 19, 2017
finance.yahoo.com - December 19 at 4:39 PM
Comparing Insulet (PODD) & Delcath Systems (DCTHD)Comparing Insulet (PODD) & Delcath Systems (DCTHD)
www.americanbankingnews.com - December 17 at 1:30 PM
Barclays Reiterates "Buy" Rating for Insulet (PODD)Barclays Reiterates "Buy" Rating for Insulet (PODD)
www.americanbankingnews.com - December 17 at 11:26 AM
Comparing Insulet (PODD) and Delcath Systems (DCTHD)Comparing Insulet (PODD) and Delcath Systems (DCTHD)
www.americanbankingnews.com - December 15 at 1:36 PM
Free Research Report as Insulet’s Revenue Grew 28.4%Free Research Report as Insulet’s Revenue Grew 28.4%
finance.yahoo.com - December 14 at 10:21 AM
Insulet (PODD) & Delcath Systems (DCTHD) Critical ReviewInsulet (PODD) & Delcath Systems (DCTHD) Critical Review
www.americanbankingnews.com - December 10 at 9:36 AM
Critical Review: Delcath Systems (DCTHD) & Insulet (PODD)Critical Review: Delcath Systems (DCTHD) & Insulet (PODD)
www.americanbankingnews.com - December 8 at 11:30 PM
Zacks: Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $125.25 MillionZacks: Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $125.25 Million
www.americanbankingnews.com - December 8 at 2:52 PM
-$0.07 EPS Expected for Insulet Co. (PODD) This Quarter-$0.07 EPS Expected for Insulet Co. (PODD) This Quarter
www.americanbankingnews.com - December 6 at 3:12 AM
Insulet (PODD) Downgraded to Hold at BidaskClubInsulet (PODD) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - December 2 at 11:54 AM
Insulet Corporation (PODD) Given Average Rating of "Buy" by BrokeragesInsulet Corporation (PODD) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 30 at 11:48 PM
ETFs with exposure to Insulet Corp. : November 28, 2017ETFs with exposure to Insulet Corp. : November 28, 2017
finance.yahoo.com - November 28 at 4:38 PM
Reviewing Delcath Systems (DCTHD) & Insulet Corporation (PODD)Reviewing Delcath Systems (DCTHD) & Insulet Corporation (PODD)
www.americanbankingnews.com - November 22 at 3:18 AM
Insulet Corporation (PODD) Price Target Increased to $75.00 by Analysts at Barclays PLCInsulet Corporation (PODD) Price Target Increased to $75.00 by Analysts at Barclays PLC
www.americanbankingnews.com - November 20 at 3:32 PM
 Analysts Expect Insulet Corporation (PODD) Will Announce Quarterly Sales of $125.25 Million Analysts Expect Insulet Corporation (PODD) Will Announce Quarterly Sales of $125.25 Million
www.americanbankingnews.com - November 20 at 2:26 PM
Financial Comparison: Insulet Corporation (PODD) versus Delcath Systems (DCTHD)Financial Comparison: Insulet Corporation (PODD) versus Delcath Systems (DCTHD)
www.americanbankingnews.com - November 20 at 1:42 PM
Insulet Corporation (PODD) Expected to Post Earnings of -$0.07 Per ShareInsulet Corporation (PODD) Expected to Post Earnings of -$0.07 Per Share
www.americanbankingnews.com - November 18 at 7:40 AM
Insulet Corporation (PODD) Director Purchases $168,625.00 in StockInsulet Corporation (PODD) Director Purchases $168,625.00 in Stock
www.americanbankingnews.com - November 14 at 8:26 PM
Insulet Corporation to Present at Upcoming Investor ConferenceInsulet Corporation to Present at Upcoming Investor Conference
finance.yahoo.com - November 14 at 6:54 AM
ETFs with exposure to Insulet Corp. : November 13, 2017ETFs with exposure to Insulet Corp. : November 13, 2017
finance.yahoo.com - November 14 at 6:54 AM
Insulet Corporation (PODD) Cut to "Hold" at Zacks Investment ResearchInsulet Corporation (PODD) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 7:16 AM
Insulet Announces Pricing of Convertible Senior Notes Due 2024Insulet Announces Pricing of Convertible Senior Notes Due 2024
finance.yahoo.com - November 9 at 11:46 AM
Insulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : November 6, 2017Insulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : November 6, 2017
finance.yahoo.com - November 7 at 8:55 AM
Insulet Announces Private Offering of Convertible Senior NotesInsulet Announces Private Offering of Convertible Senior Notes
finance.yahoo.com - November 7 at 8:55 AM
Insulet Corp. :PODD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Insulet Corp. :PODD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 8:55 AM
Insulet Corporation Expected to Post FY2021 Earnings of $1.61 Per Share (PODD)Insulet Corporation Expected to Post FY2021 Earnings of $1.61 Per Share (PODD)
www.americanbankingnews.com - November 6 at 2:22 PM
Q3 2018 EPS Estimates for Insulet Corporation Raised by Analyst (PODD)Q3 2018 EPS Estimates for Insulet Corporation Raised by Analyst (PODD)
www.americanbankingnews.com - November 6 at 12:30 PM
Insulet Co. (PODD) Given Consensus Rating of "Buy" by AnalystsInsulet Co. (PODD) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 9:30 PM
Insulet Corporation (PODD) PT Raised to $72.00 at Robert W. BairdInsulet Corporation (PODD) PT Raised to $72.00 at Robert W. Baird
www.americanbankingnews.com - November 5 at 7:42 AM
Insulet Corporation (PODD) PT Raised to $67.00 at Jefferies Group LLCInsulet Corporation (PODD) PT Raised to $67.00 at Jefferies Group LLC
www.americanbankingnews.com - November 5 at 7:16 AM
Insulet Corporation (PODD) Given New $63.00 Price Target at Morgan StanleyInsulet Corporation (PODD) Given New $63.00 Price Target at Morgan Stanley
www.americanbankingnews.com - November 5 at 7:16 AM
Insulet Reports Third Quarter 2017 Financial ResultsInsulet Reports Third Quarter 2017 Financial Results
www.businesswire.com - November 4 at 9:02 AM
Insulet Corp. (PODD) Has Surged To A New High After Q3 Loss NarrowsInsulet Corp. (PODD) Has Surged To A New High After Q3 Loss Narrows
www.nasdaq.com - November 4 at 9:02 AM
Insulet (PODD) Q3 2017 Results - Earnings Call TranscriptInsulet (PODD) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 4 at 9:02 AM
Here's Why Insulet Corporation's Investors Are PumpedHere's Why Insulet Corporation's Investors Are Pumped
finance.yahoo.com - November 4 at 9:02 AM
Edited Transcript of PODD earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of PODD earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 9:02 AM
Insulet Corporation (PODD) Posts  Earnings Results, Beats Estimates By $0.06 EPSInsulet Corporation (PODD) Posts Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - November 3 at 6:24 PM

SEC Filings

Insulet (NASDAQ:PODD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insulet (NASDAQ:PODD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insulet (NASDAQ PODD) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.